![](https://library.celltelligence.com/wp-content/uploads/2023/12/Screenshot-2023-12-14-at-16.33.13.png)
$0
Obe-cel Demonstrates Promising Efficacy in Patients with Low Leukemia Burden; Pooled Analysis from ALLCAR19 and FELIX Trials Suggests Long Durability of Response; ASH 2023 Analysis 2
ASH 2023 Analysis 2: Autolus presented updated clinical data from its lead asset obe-cel (CD19 CAR-T). Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below: